SCYX Stock Analysis: Buy, Sell, or Hold?
SCYX - SCYNEXIS, Inc.
$4.67
-0.43 (-8.43%)
▼
5d:
+566.29%
30d:
+374.5%
90d:
+502.58%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When SCYX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: SCYX is 78.2% above its trading range ($2.62). Market expects 0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: SCYX is 78.2% above its trading range ($2.62). Market expects 0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: SCYX is currently trading at $4.67, which is considered extended relative to its 30-day fair value range of $-0.04 to $2.62. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.9) compared to its historical average (1.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SCYX is in a uptrend. Immediate support is located at $0.63, while resistance sits at $5.62. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: SCYX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $33.55 (+618.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SCYX is in a uptrend. Immediate support is located at $0.63, while resistance sits at $5.62. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: SCYX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $33.55 (+618.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$-0.04 -
$2.62
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
All Signals
- BEARISH: Price significantly overextended (+78.2% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.4%)
- BULLISH: Trading 618.3% below Wall St target ($33.55)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to 78.2% overvaluation
Trading Range Analysis
30-Day Trading Range
$-0.04 -
$2.62
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.63
Resistance Level
$5.62
Current Trend
Uptrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.85
Wall Street Target
$33.55
(+618.3%)
Revenue Growth (YoY)
1808.5%
Profit Margin
-120.5%
PE vs Historical
-1.9 vs 1.5
CHEAP
Share & Embed Analysis
Last updated: June 03, 2026 8:05 PM ET
Data refreshes hourly during market hours. Next update: 9:05 PM
Data refreshes hourly during market hours. Next update: 9:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SCYX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$192 | 66 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 60 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 56 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 55 HOLD |
